Edwards Lifesciences' Next Act: TMTT Surges as TAVR Enters New Era

IRVINE, Calif. – November 04, 2026 – For years, the narrative surrounding Edwards Lifesciences has been inextricably linked to the transcatheter aortic valve replacement (TAVR) market it helped pioneer. But the company’s third-quarter 2026 financial results reveal a compelling strategic pivot. As the core TAVR market matures, Edwards is successfully scaling its newer mitral and tricuspid franchises into double-digit growth engines, fundamentally reshaping its revenue profile and reducing its reliance on a single flagship therapy.

The Irvine-based medical technology giant reported third-quarter net sales of $1.72 billion, representing an 11.2% increase on a constant-currency basis. This broad-based structural heart demand prompted management to raise its full-year 2026 outlook across total sales, TAVR, and adjusted earnings per share. Yet, beneath the bullish guidance lies a complex financial quarter marked by significant asset impairments and shifting regulatory landscapes.

For professionals monitoring the intersection of medical innovation and market dynamics, Edwards’ latest quarter offers a clear diagnosis of an industry in the early innings of a major transformation.

Beyond TAVR: The Mitral and Tricuspid Growth Engine

The most striking takeaway from the third-quarter report is the explosive growth of the company’s Transcatheter Mitral and Tricuspid Therapies (TMTT) division. TMTT revenue surged 45.6% on a constant-currency basis to $207 million, driven by the rapid adoption of the PASCAL and EVOQUE platforms.

This performance underscores a critical transition. While TAVR remains the financial bedrock—growing 8.8% in constant currency to $1.24 billion—the TMTT portfolio is rapidly becoming the company's primary growth catalyst. Globally, mitral and tricuspid procedure volumes are expanding in the double digits, and Edwards is aggressively capturing market share in a space historically dominated by competitors like Abbott Laboratories.

Recent regulatory victories have fortified this position. During the quarter, Edwards secured U.S. Food and Drug Administration (FDA) approval for the PASCAL Ace with Capture Clarity implant for degenerative mitral procedures, introducing novel indicators that simplify the notoriously challenging step of leaflet grasping. Shortly after, the FDA approved the PASCAL Precision system for tricuspid regurgitation.

These approvals effectively complete Edwards' portfolio of repair and replacement therapies for both mitral and tricuspid valves in the United States. Early clinician feedback has been overwhelmingly positive, particularly regarding the EVOQUE system, which recently received U.S. and European approval for transjugular access. As physicians gain experience with these therapies, they are consistently achieving mild or less residual regurgitation, a clinical endpoint increasingly linked to superior patient outcomes.

The TMTT market is highly competitive, with Abbott’s MitraClip and TriClip systems deeply entrenched in hospital workflows. However, Edwards’ 45% growth rate suggests that its differentiated portfolio approach—offering both repair and replacement options tailored to complex anatomies—is successfully disrupting the status quo.

Earlier and Broader: Policy Shifts and the PROGRESS Trial

Even as TMTT takes the spotlight, the TAVR market is undergoing a quiet revolution driven by new clinical data and updated reimbursement policies. For years, the standard of care for moderate aortic stenosis (AS) has been "watchful waiting"—a passive surveillance strategy until the disease progresses to a severe state.

That paradigm is now fracturing. At the recent Transcatheter Cardiovascular Therapeutics (TCT) 2026 conference, Edwards presented results from the PROGRESS trial, which were simultaneously published in The New England Journal of Medicine. The trial demonstrated superior outcomes for TAVR in moderate AS patients with at-risk features, challenging the longstanding practice of clinical surveillance.

This data represents a turning point in disease management. By proving that earlier intervention yields significant clinical benefits, Edwards is laying the groundwork to expand TAVR indications to a patient population that outnumbers severe AS patients nearly two to one.

Simultaneously, the regulatory environment is shifting to accommodate this proactive approach. During the third quarter, the Centers for Medicare & Medicaid Services (CMS) released its final updated National Coverage Determination (NCD) for TAVR. Crucially, the updated policy expands coverage to asymptomatic patients and provides a pathway for future indications.

“We delivered strong third-quarter growth of 11.2% which exceeded expectations, with broad-based performance across our businesses and regions, giving us the confidence to raise our full-year outlook,” said Bernard Zovighian, CEO of Edwards Lifesciences. “Our focused structural heart strategy, coupled with disciplined execution, long-term investments in category-creating innovation, and commitment to science and technology advancements, enabled us to deliver significant progress for patients on several of our most important clinical, regulatory, policy and commercial priorities this quarter.”

Hospital administrators and healthcare policy specialists note that while the NCD's impact on procedural volumes will be gradual, it fundamentally alters the financial viability of proactive disease management. By aligning Medicare reimbursement with the latest clinical evidence, CMS is removing a major barrier to earlier intervention.

Unpacking the Earnings Gap: Guidance Hikes vs. Balance Sheet Realities

Despite the operational triumphs and bullish forward-looking guidance, Edwards’ third-quarter balance sheet reveals the inherent risks of aggressive structural heart innovation. The company reported a stark divergence between its adjusted earnings per share of $0.80 (a 19% year-over-year increase) and its GAAP EPS of just $0.53.

The primary culprit for this earnings gap is a massive $220.2 million impairment charge on intangible and long-lived assets. While the earnings release broadly attributed this to a "certain in-process research and development asset," the broader context of Edwards' recent mergers and acquisitions activity provides necessary clarity.

In early 2026, the Federal Trade Commission successfully blocked Edwards’ proposed $945 million acquisition of JenaValve Technology, citing antitrust concerns in the development of devices for aortic regurgitation. Following the injunction, Edwards abandoned the deal. The $220 million write-down is widely understood by financial analysts to be tied to the re-evaluation of internal or previously acquired early-stage assets in the aortic regurgitation space that failed to meet revised expectations in the wake of the collapsed JenaValve transaction.

Further complicating the GAAP financials are significant tax headwinds. The company recorded a $174.4 million valuation allowance against certain deferred tax assets, driven by recent California budget legislation that permanently limits the usage of research and development tax credit carryovers.

Yet, Wall Street appears willing to look past these one-time GAAP hits, focusing instead on the underlying operational momentum. Edwards increased its full-year 2026 sales growth rate guidance to approximately 11.5%, up from a previous range of 10% to 11%. The company also bumped its TAVR sales growth guidance to 9.0% to 9.5% and raised its adjusted EPS guidance to $2.97 to $3.05.

This confidence is rooted in the underlying market dynamics. Exiting the third quarter, Edwards reported encouraging signs of procedure growth globally. The company is no longer relying solely on market share gains to drive TAVR revenue; instead, it is benefiting from a structural expansion of the market itself, fueled by updated clinical guidelines and proactive disease management.

As Edwards Lifesciences navigates the remainder of 2026, the company stands at a fascinating inflection point. The costly R&D write-downs serve as a stark reminder of the high-stakes nature of medical device innovation. However, the explosive growth of the mitral and tricuspid portfolio, combined with the regulatory and clinical tailwinds expanding the TAVR market, suggests that the company's long-term structural heart strategy is yielding tangible results. The era of relying on a single valve is ending, making way for a diversified, multi-therapy approach to cardiovascular care.